REPROCELL News | Drug Discovery

Jul 02, 2025

Scottish Health Minister Visits REPROCELL Japan to Strengthen Life Sciences Collaboration

Scottish Health Minister Neil Gray visits REPROCELL Japan to enhance life sciences collaboration, highlighting strong ties and innovative healthcare advancements between Scotland and Japan.

Feb 08, 2024

PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

REPROCELL will soon add a third clinical pipeline, TIL therapy for cervical cancer, in addition to Stemchymal for spinocerebellar ataxia, and iPSC-derived neuroglial cells for ALS.

Dec 15, 2023

End of 2023 Newsletter

Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.

Oct 24, 2023

REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study

REPROCELL supports Silo Pharma research success, investigating the effects of SPU-21 Peptide on rheumatoid arthritis in a human synovial tissue study

Jun 01, 2023

Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform

REPROCELL has collaborated with HNCDI to create a machine learning (ML) platform that simplifies and accelerates the analysis of big data from drug development studies.

Dec 09, 2022

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

The three-month study, conducted at REPROCELL, will assess the binding affinity of the peptide in healthy human and RA synovial tissue.

Nov 09, 2022

Building economic resilience and unleashing productivity through digital innovation

CEO of REPROCELL said his company was among those that had received support from HNCDI to help it develop new approaches to drug development.

Aug 31, 2022

REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine

Collaboration at Hartree NCDI combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in AI and machine learning.

Aug 17, 2022

Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials

Learn how scientists at REPROCELL compared the effects of RCD405 with drugs that are currently used to treat respiratory disease in human living bronchi.

Aug 15, 2022

Life science after lockdown: SPS returns for 2022

Discover the first, in-person Saftey Pharmacology Society annual meeting since 2019: a dynamic forum, known for its global networking opportunities.

Mar 08, 2022

REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development

Read how REPROCELL and IBM developed a novel Machine Learning driven precision medicine strategy for drug development.

Jan 21, 2022

REPROCELL spotlights the power of smarter biospecimens in new global publication

REPROCELL has published an article highlighting the power of biospecimens in EBR. Visit the news section of our website to find out more.

Oct 25, 2021

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

Hoth Therapeutics has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in IBD. Find out why.

Jul 05, 2021

REPROCELL highlights the power of human fresh tissue in global publication

This article explains the benefits of human fresh tissue testing in drug discovery, describing studies where these assays have helped clinical trials.

Mar 15, 2021

Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease

Hoth Therapeutics has executed a partnership agreement with REPROCELL to assess the effect of its HT-003 therapeutic platform on tissue from IBD donors.

Jul 16, 2020

eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations

Learn more about how eTheRNA's mRNA covid vaccine, developed in partnership with REPROCELL, is designed to be protective against future viral variations.

Jul 13, 2020